Archive for the 'Pharmacy' Category

16 DecAgios Pharmaceuticals to present AG-221 Phase 1 study results at EHA meeting Agios Pharmaceuticals.

Title: A Phase I Research of AG-221, an initial in Class, Powerful Inhibitor of the IDH2-Mutant Protein, in Patients with IDH2 Mutant Positive Advanced Hematologic Malignancies Demonstration time: Saturday, June 14 at 1:30 p.m. CEST Session title: Later breaking1 Presenter: Stephane De Botton, M.D., Institut de Cancerologie Gustave Roussy, Villejuif, France Abstract code: LB2434 Conference Call Information Agios will sponsor a conference contact and webcast on Monday, June 16, 2014, at 8:30 a.m. EDT to examine the clinical data shown at EHA from the ongoing Phase 1 study of AG-221.Â.. Agios Pharmaceuticals to present AG-221 Phase 1 study results at EHA meeting Agios Pharmaceuticals, Inc. , a head in the areas of cancer rate of metabolism and inborn errors of metabolism , announced that new clinical data from the Phase 1 research of AG-221 today, an available orally, selective, potent inhibitor of the mutated IDH2 proteins, will be highlighted in an oral display at the 19th Congress of the European Hematology Association occurring June 12 -15, 2014 in Milan, Italy. Read more…

05 DecAn investigational medication candidate in development for schizophrenia.

This is actually the initial demonstration of the efficacy of a variety of dosages of a long-acting injectable form of aripiprazole in a randomized scientific trial. The company remains on track to submit a New Drug Software to the U.S. Food and Drug Administration in the 3rd quarter of 2014. ‘With these compelling phase 3 data at hand, we are moving forward expeditiously to bring aripiprazole lauroxil to sufferers with schizophrenia and their families,’ said Serge Stankovic, M.D., MSPH, Senior Vice President, Clinical Medical and Advancement Affairs of Alkermes. ‘With a deep background in the development of long-performing injectable antipsychotic medicines, our researchers designed aripiprazole lauroxil rationally, in a ready-to-make use of format with multiple dosing choices, to meet the individual needs of patients and the doctors and nurses who treat them.’ Data from the entire analysis set of the phase 3 study showed: During the 12-week, double-blind treatment period, patients treated once-regular with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically and clinically significant placebo-adjusted indicate reductions from baseline in PANSS total scores . Read more…

30 Nov4 million performed in 2005.

Another notable tendency – collagen and fat injections have decreased 58 and 13 % respectively since 2004, but on the rise are hyaluronic acid , polylactic acid , and calcium hydroxylapatite fillers. This could be attributed to the fact that collagen and excess fat injections can be frustrating with allergy checks and harvesting techniques, and the newer fillers can achieve similar, if not better, results. To secure a full report of the 2005 National Clearinghouse of Plastic Surgery Statistics, which include trending data on gender, age, geography, surgeons charges, ethnicity and more, contact ASPS PR. Since 2003, statistics have been collected through the initial online national database for plastic surgery procedures, Tracking Operations and Outcomes for Plastic Surgeons . Read more…

23 NovPRESS RELEASE DUBLINandALISO VIEJO.

XEN45 offers received a CE mark in europe where it is indicated for the reduced amount of intraocular pressure in individuals with primary open angle glaucoma where previous procedures have failed. The CE mark allows treatment in conjunction with a cataract procedure or as a standalone process. XEN45 can be approved for use inTurkey,CanadaandSwitzerland. AqueSys is pursuing reimbursement in these national countries. Inthe USA, XEN45 is certainly in late-stage advancement, with the final US Investigational Device Exemption clinical trial fully enrolled in the second quarter of 2015. Read more…

09 NovAfrica needs policies.

Africa needs policies, rules to spur development of innovative cellular phone-based applications Also needed work policies and regulations to spur development of innovative mobile phone-based applicationsThe fast-growing usage of cell phones in Africa – where many people lack the essential human necessities – has produced headlines worldwide the past few years vigrx oil . The astonishing boom has led to widespread speculation that cell phones could potentially transform the impoverished continent. But new study by economists Isaac M. Jenny and Mbiti C. Aker has found that cell phones – while a useful and powerful device for many people in Africa – cannot travel economic development on their own. Read more…

04 NovWednesday which goes on sale.

2nd test of prostate cancer aggressiveness hits market A fresh genetic test to gauge the aggressiveness of prostate cancer can help tens of thousands of men each year decide whether they have to treat their cancer right away or can securely monitor it. The new test, wednesday which goes on sale, joins a different one that came out there recently http://priligy4u.com/dapoxetine . Both evaluate multiple genes in a biopsy sample and give a rating for aggressiveness, similar to tests used right now for certain breasts and colon cancers. Read more…

01 NovAasma Shaukat.

Geisser, M.S., Frank A. Lederle, M.D., John H. Bond, M.D., Jack S. Mandel, Ph.D., M.P.H., and Timothy R. Church, Ph.D.: Long-Term Mortality after Screening for Colorectal Cancer Estimates from multiple, large, randomized trials of colorectal-tumor screening with fecal occult-blood testing consistently display a decrease in colorectal-malignancy mortality of 15 to 33 percent.1-4 The longest follow-up reported to day is 18 to 20 years.5-7 Whether the aftereffect of screening on colorectal-tumor mortality is sustained and whether it pertains to all age groups and both sexes are unfamiliar. Furthermore, non-e of the trials have shown a reduction in all-cause mortality, and one meta-analysis demonstrated a significant increase in mortality not linked to colorectal cancer.8 We updated the Minnesota CANCER OF THE COLON Control Study9 through 30 years of follow-up to assess the long-term aftereffect of screening on colorectal-cancer mortality and all-cause mortality also to evaluate effects specific to age and sex. Read more…

08 OctNezam Afdhal.

Nezam Afdhal, M article .D., Stefan Zeuzem, M.D., Paul Kwo, M.D., Mario Chojkier, M.D., Norman Gitlin, M.D., Massimo Puoti, M.D., Manuel Romero-Gomez, M.D., Ph.D., Jean-Pierre Zarski, M.D., Ph.D., Kosh Agarwal, M.D., Peter Buggisch, M.D., Graham R. Foster, Ph.D.D., M.B.A., Maria Buti, M.D., Ph.D., Ira M. Jacobson, M.D., G. Mani Subramanian, M.D., Ph.D., Xiao Ding, Ph.D., Hongmei Mo, M.D., Jenny C. Yang, Pharm.D., Phillip S. Pang, M.D., Ph.D., William T. Symonds, Pharm.D., John G. McHutchison, M.D., Andrew J. Muir, M.D., M.H.S., Alessandra Mangia, M.D., and Patrick Marcellin, M.D., Ph.D. Read more…

07 OctWhat you can do for her?

She has rarely worn lipstick since the problem began. On examination, the lips are swollen and erythematous, which prolong beyond the external margin . Marked improvement happens with use of an antibiotic and corticosteroid ointment, but the nagging problem returns within days of ceasing treatment. Can be allergy to a lipbalm component likely? How must i proceed?. A 33-year-old woman with sore red lips A young woman presents with a past history of sore lips that are dried out and sometimes extremely flaky. What you can do for her? Case scenario A healthy 33-year-old female presents with a three-month history of dried out, sore, red and sometimes very flaky lips. Read more…

04 OctACP disappointed simply by cloture vote in S.

1776 cannot be the end of the complete story. ACP will continue steadily to insist that Congress repeal the unworkable and destabilizing Medicare SGR and create an improved system for updating doctor providers. Congress must end the practice of enacting short-term patches that neglect to provide the balance needed to initiate comprehensive doctor payment reform or the assurance sufferers need that their access will not be reduced by devastating physician payment cuts. Finally, the American College of Doctors rejects the cynical charge created by some that physicians’ support for health care reform is definitely conditioned on repeal of the SGR. Read more…